Revier Therapeutics Secures $7 Million in Latest Seed Funding Round

Revier Therapeutics secured $7 million in its latest Seed, adding another data point to the Healthcare & Life Sciences funding market.

Revier Therapeutics Raises $7 million in Funding

Heidelberg-based Revier Therapeutics launched with a EUR 6M (~$7.0M) seed financing to develop first-in-class selective class IIa HDAC inhibitors for cardiometabolic disease.

Investors Behind the Funding

The round was backed by KHAN Technology Transfer Fund II. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Revier Therapeutics operates in Healthcare & Life Sciences. Cardiometabolic disease, and HFpEF in particular, remains one of the largest untreated indications in cardiology. Epigenetic targets long considered undruggable are being revisited with selective small molecules that spare essential enzyme functions. German technology-transfer funds are seeding academic spinouts directly out of university cardiology programmes.

Strategic Use of Funds

Advance the preclinical cardiometabolic pipeline including lead HFpEF and second ASCVD programmes, and build out operational, scientific and clinical functions

Looking Ahead

Revier's first-in-class small molecules selectively target class IIa HDACs, inhibiting disease-driving enzymatic activity while preserving essential functions.

Source reference: original announcement/article.